Evidence map›Paper›PMID 21115858›Full record

ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2011

Associations of insulin resistance and adiponectin with mortality in women with breast cancer.

Catherine Duggan, Melinda L Irwin, Liren Xiao, Katherine D Henderson, Ashley Wilder Smith, Richard N Baumgartner, Kathy B Baumgartner, Leslie Bernstein, Rachel Ballard-Barbash, Anne McTiernan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 140 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
140citing papers in PubMed, 3 pooled it
12.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

140 citing papers in PubMed, 3 syntheses or guidelines pooled it, 293 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Exercise and dietary advice intervention for survivors of triple-negative breast cancer: effects on body fat, physical function, quality of life, and adipokine profile.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2015
    Trial
  11. Trial
  12. Trial
  13. The effect of aerobic exercise on metabolic and inflammatory markers in breast cancer survivors--a pilot study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2013
    Trial
  14. Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2012
    Trial
  15. Trial
  16. Trial
  17. Trial
  18. Review
  19. Review
  20. Review

80 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Catherine DugganPublic Health Sciences, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N., MD-B306, Seattle, WA 98104, USA. cduggan@fhcrc.org
Melinda L Irwin
Liren Xiao
Katherine D Henderson
Ashley Wilder Smith
Richard N Baumgartner
Kathy B Baumgartner
Leslie Bernstein
Rachel Ballard-Barbash
Anne McTiernan
Fred Hutch Cancer Center · USYale University · USCity Of Hope National Medical Center · USNational Cancer Institute · US

Funding

INSTITUTE FOR TRANSLATIONAL HEALTH SCIENCE (UL1): BPCAUL1RR025014 · NCRR · UNIVERSITY OF WASHINGTON · PI DISIS, MARY L. · 2007 to 2011
$51.5M
ZIPRASIDONE IN NORMAL HEPATIC FUNCTION SUBJECTS &IN HEPATIC DYSFUCTIN SUBJECTSM01RR000037 · NCRR · UNIVERSITY OF WASHINGTON · PI PIHOKER, CATHERINE · 1985 to 2007
$33.8M
ZUNI KIDNEY PROJECT STUDY I--POPULATION BASED SURVEY OF RENAL DISEASEM01RR000997 · NCRR · UNIVERSITY OF NEW MEXICO · PI MERTZ, GREGORY JAMES · 1985 to 2010
$30.0M
Preventing obesity in low income working adultsU54CA116847 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI MCTIERNAN, ANNE M. · 2005 to 2010
$12.6M
USC Center for Transdisciplinary Research on Energetics*U54CA116848 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI GORAN, MICHAEL ISAAC · 2005 to 2010
$12.1M
Cancer Prevention Trng-Nutrition, Exercise &GeneticsR25CA094880 · NCI · UNIVERSITY OF WASHINGTON · PI WHITE, EMILY · 2002 to 2016
$7.3M
SURVEILLANCE EPIDEMIOLOGY &END RESULTS PROGRAMN01PC067010 · PC · UNIVERSITY OF SOUTHERN CALIFORNIA · PI ROSS, RONALD K · 1996 to 2000
$2.4M
BREAST CANCER AND THE BIRTH CONTROL PILL-275933175N01HD033175 · NICHD · UNIVERSITY OF SOUTHERN CALIFORNIA · 1993 to 2003
$298k
SURVEILLANCE, EPIDEMIOLOGY, AND END RESULTSN01CN005228 · CN · UNIVERSITY OF NEW MEXICO · PI KEY, CHARLES · 1990 to 1996
–
NCI NIH HHS N01 CN005228NCI NIH HHS N01-CN-05228NCI NIH HHS N01-CN-75036-20NCI NIH HHS N01 PC067010NCI NIH HHS R25 CA094880NCI NIH HHS R25-CA94880NCI NIH HHS U54 CA116847NCI NIH HHS U54-CA116847NCI NIH HHS U54 CA116848NCI NIH HHS U54CA116848NCRR NIH HHS M01 RR000037NCRR NIH HHS M01-RR-00037NCRR NIH HHS M01 RR000997NCRR NIH HHS M01-RR-0997NCRR NIH HHS UL1 RR025014NICHD NIH HHS N01-HD-3-3175
6 · The paper itself

Abstract

purposeOverweight or obese breast cancer patients have a worse prognosis compared with normal-weight patients. This may be attributed to hyperinsulinemia and dysregulation of adipokine levels associated with overweight and obesity. Here, we evaluate whether low levels of adiponectin and a greater level of insulin resistance are associated with breast cancer mortality and all-cause mortality. PATIENTS AND

methodsWe measured glucose, insulin, and adiponectin levels in fasting serum samples from 527 women enrolled in the Health, Eating, Activity, and Lifestyle (HEAL) Study, a multiethnic, prospective cohort study of women diagnosed with stage I-IIIA breast cancer. We evaluated the association between adiponectin and insulin and glucose levels (expressed as the Homeostatic Model Assessment [HOMA] score) represented as continuous measures and median split categories, along with breast cancer mortality and all-cause mortality, using Cox proportional hazards models.

resultsIncreasing HOMA scores were associated with reduced breast cancer survival (hazard ratio [HR], 1.12; 95% CI, 1.05 to 1.20) and reduced all-cause survival (HR, 1.09; 95% CI, 1.02 to 1.15) after adjustment for possible confounders. Higher levels of adiponectin (above the median: 15.5 μg/mL) were associated with longer breast cancer survival (HR, 0.39; 95% CI, 0.15 to 0.95) after adjustment for covariates. A continuous measure of adiponectin was not associated with either breast cancer-specific or all-cause mortality.

conclusionElevated HOMA scores and low levels of adiponectin, both associated with obesity, were associated with increased breast cancer mortality. To the best of our knowledge, this is the first demonstration of the association between low levels of adiponectin and increased breast cancer mortality in breast cancer survivors.

Indexed as

Insulin ResistanceAdiponectinAdultAgedAged, 80 and overBlood GlucoseBody Mass IndexBody WeightBreast NeoplasmsCohort StudiesFemaleHumansHyperinsulinismInsulinMiddle AgedObesityAdiponectinBlood GlucoseInsulin

Identifiers

PMID21115858
PMCPMC3055857
OpenAlexW2151396655

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.